U.S. In Vitro Diagnostics (IVD) Market by Technology (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Microbiology), Application (Infectious Diseases, Diabetes, Cancer, Cardiology), End User (Hospitals & Laboratories) & by Region - Forecast to 2020

アメリカの体外診断(IVD)市場:免疫測定法、臨床化学、分子診断、微生物

◆タイトル:U.S. In Vitro Diagnostics (IVD) Market by Technology (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Microbiology), Application (Infectious Diseases, Diabetes, Cancer, Cardiology), End User (Hospitals & Laboratories) & by Region - Forecast to 2020
◆商品コード:MAM-MD-4174
◆調査・発行会社:MarketsandMarkets
◆発行日:2016年3月17日
◆ページ数:179
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:米国
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single UserUSD12,000 ⇒換算¥1,356,000見積依頼/購入/質問フォーム
Multi User (Five User)USD15,000 ⇒換算¥1,695,000見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD18,000 ⇒換算¥2,034,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"アメリカの体外診断(IVD)市場:免疫測定法、臨床化学、分子診断、微生物"について調査・分析し、イントロダクション、エグゼクティブサマリー、プレミアムインサイト、市場概観、市場の動態、技術別分析、製品別分析、用途別分析、需要先別分析、市場規模及び予測、競争状況、市場シェア分析、新製品発売、主要企業(ベンダー)分析等の情報をお届けいたします。

The U.S. is a prime market due to the availability of government funds, expansion of molecular diagnostics for genetic disorders and cancer screening, and easy access to IVD tests through diagnostic service providers and major leading companies headquartered in the U.S. The U.S. in vitro diagnostics market is estimated to reach USD 25.99 Billion by 2020, growing at a CAGR of 4.7% during the forecast period. This market is primarily driven by the rising incidence of chronic and infectious diseases, rapidly aging population, increasing demand for automated high-throughput instruments, increasing automation in laboratories, implementation of Affordable Care Act (ACA), and rise in point-of-care testing and personalized medicine. Additionally, extending reach of molecular diagnostics and new range of condition-specific markers and tests with advances in genomics and proteomics are creating new opportunities for this market. However, stringent regulatory framework presents significant challenges to market growth.

In this report, the market is segmented on the basis of products & services, technologies, applications, end users, and regions. The research report discusses key market drivers, restraints, opportunities, and challenges in the U.S. IVD market and its submarkets.

The U.S. IVD product & services market is broadly segmented into reagents, instruments, services, and data management system/software. The reagents segment accounted for the largest share of the U.S IVD product & service market in 2014, and is expected to grow at a highest CAGR during the forecast period of 2015 to 2020. The accessibility of a wide range of reagents and the need for reliable, specific, and faster detection of chronic diseases and genetic disorders at early stages are driving the market growth in this product segment.

On the basis of technology, the U.S. IVD market is broadly segmented into immunoassays/immunochemistry, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation/hemostasis, and others. Of these, the immunoassays/immunochemistry segment accounted for the largest share of the U.S. market in 2014. The ability of immunoassay/immunochemistry technologies to offer faster results with high sensitivity and accuracy is one of the key factors contributing to the growth of this market over other technologies.

The U.S. IVD market by region is segmented into South, Midwest, West, and Northeast region. In 2014, the South region commanded the largest share of the U.S. IVD market, followed by West. However, the Midwest region is expected to witness the highest growth largely driven by the increasing number of accredited laboratories, reimbursement by the Medicare, growing demand for technologically advanced diagnosis devices, and increased spending capabilities of consumers on healthcare.

The major players in the U.S. IVD market are Roche Diagnostics Limited (Switzerland), Abbott Laboratories, Inc. (U.S.), Becton, Dickson and Company (U.S.), Johnson & Johnson (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Siemens Healthcare (Germany), Bio-Rad Laboratories, Inc. (U.S.), Sysmex Corporation (Japan), QIAGEN N.V. (Netherlands), Alere Inc. (U.S.), Ortho-Clinical Diagnostics Inc. (U.S.), and bioM¨¦rieux (France).

【レポートの目次】

1 Introduction (Page No. – 14)
1.1 Objectives of The Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for The Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology (Page No. – 17)
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.2 Market Size Estimation
2.3 Market Breakdown and Data Triangulation
2.4 Market Share Estimation
2.5 Assumptions for The Study

3 Executive Summary (Page No. – 24)

4 Premium Insights (Page No. – 29)
4.1 Growth Potential of The U.S. in Vitro Diagnostics Market
4.2 U.S. in Vitro Diagnostics Market, By End User (2014)
4.3 U.S. in Vitro Diagnostics Market, Regional Mix

5 Market Overview (Page No. – 32)
5.1 Introduction
5.2 Market Segmentation
5.2.1 By Product
5.2.2 By Technology
5.2.3 By Application
5.2.4 By End User
5.3 Market Dynamics
5.3.1 Drivers
5.3.1.1 Rapid Growth in Geriatric Population and Increasing Incidence of Chronic Diseases in The U.S.
5.3.1.2 Increasing Adoption of Point-Of-Care (POC) Testing
5.3.1.3 Growing Awareness on Personalized Medicine
5.3.1.4 Rise in Reagent Rental Agreements
5.3.1.5 Implementation of The Affordable Care Act (ACA)
5.3.1.6 Increasing Adoption of Automated Instruments and Automation in Laboratories
5.3.2 Restraints
5.3.2.1 Unfavorable Reimbursement Scenario
5.3.2.2 Rising Healthcare Costs and Low Budgets
5.3.3 Opportunities
5.3.3.1 Condition-Specific Markers and Tests With Advances in Genomics and Proteomics
5.3.4 Challenges
5.3.4.1 Stringent Regulatory Framework

6 U.S. in Vitro Diagnostics Market, By Product & Service (Page No. – 43)
6.1 Introduction
6.2 Reagents
6.3 Instruments
6.3.1 Fully Automated Instruments
6.3.2 Semi-Automated Instruments
6.3.3 Others
6.4 Data Management Software
6.5 Services

7 U.S. in Vitro Diagnostics Market, By Technology (Page No. – 52)
7.1 Introduction
7.2 Clinical Chemistry
7.3 Immunochemistry/Immunoassays
7.4 Microbiology
7.5 Molecular Diagnostics (MDX)
7.6 Hematology
7.7 Coagulation/Hemostasis
7.8 Other IVD Technologies

8 U.S. in Vitro Diagnostics Market, By Application (Page No. – 61)
8.1 Introduction
8.2 Infectious Diseases
8.3 Diabetes
8.4 Oncology/Cancer
8.5 Cardiovascular Disorders
8.6 Endocrine Disorders
8.7 Autoimmune Diseases
8.8 Bone & Mineral-Related Diseases
8.9 Pulmonary Diseases
8.10 Other Applications

9 U.S. in Vitro Diagnostics Market, By End User (Page No. – 74)
9.1 Introduction
9.2 Hospital Laboratories
9.3 Clinical/Independent Laboratories
9.3.1 Large Laboratories/Reference Laboratories
9.3.2 Medium-Sized Laboratories
9.3.3 Small Laboratories
9.4 Other End Users

10 Competitive Landscape (Page No. – 83)
10.1 Overview
10.2 Market Share Analysis
10.3 Competitive Situation and Trends
10.3.1 New Product Launches
10.3.2 Collaborations, Agreements, & Partnerships
10.3.3 Approvals
10.3.4 Mergers & Acquisitions
10.3.5 Others

11 Company Profiles (Page No. – 92)
(Overview, Financials, Products & Services, Strategy, & Developments)*
11.1 Abbott Laboratories, Inc.
11.2 Danaher Corporation
11.3 Johnson and Johnson
11.4 Roche Diagnostics
11.5 Siemens Healthcare
11.6 Becton, Dickinson and Company
11.7 Biom¨¦rieux
11.8 Bio-Rad Laboratories, Inc.
11.9 Sysmex Corporation
11.10 Thermo Fisher Scientific, Inc.
11.11 Qiagen N.V.

12 Appendix (Page No. – 149)
12.1 Insights of Industry Experts
12.2 Discussion Guide
12.3 Other Developments
12.4 Knowledge Store: Marketsandmarkets¡¯ Subscription Portal
12.5 Introducing RT: Real-Time Market Intelligence
12.6 Available Customizations
12.7 Related Reports

List of Tables (50 Tables)

Table 1 Increased Incidence of Chronic Diseases and Rapid Growth in Geriatric Population Will Drive The Market Growth
Table 2 Unfavorable Reimbursement and Rising Healthcare Costs to Restrain Market Growth
Table 3 Condition Specific Markers, an Area of Opportunity
Table 4 Stringent & Uncertain Regulations, A Key Challenge for The IVD Market
Table 5 U.S. IVD Market Size, By Product & Service, 2013¨C2020 (USD Million)
Table 6 U.S.: IVD Market Size, By Region, 2013¨C2020 (USD Million)
Table 7 U.S. IVD Reagents Market Size, By End User, 2013¨C2020 (USD Million)
Table 8 U.S. IVD Instruments Market Size, By Type, 2013¨C2020 (USD Million)
Table 9 U.S. IVD Instruments Market Size, By End User, 2013¨C2020 (USD Million)
Table 10 U.S. IVD Data Management Software Market Size, By End User, 2013¨C2020 (USD Million)
Table 11 U.S. IVD Services Market Size, By End User, 2013¨C2020 (USD Million)
Table 12 U.S. IVD Market Size, By Technology, 2013¨C2020 (USD Million)
Table 13 U.S. Clinical Chemistry Market Size, By End User, 2013¨C2020 (USD Million)
Table 14 U.S. Immunochemistry/Immunoassys Market Size, By End User, 2013¨C2020 (USD Million)
Table 15 U.S. Microbiology Market Size, By End User, 2013¨C2020 (USD Million)
Table 16 U.S. Molecular Diagnostics Market Size, By End User, 2013¨C2020 (USD Million)
Table 17 U.S. Hematology Market Size, By End User, 2013¨C2020 (USD Million)
Table 18 U.S. Coagulation/Hemostasis Market Size, By End User, 2013¨C2020 (USD Million)
Table 19 U.S. Other IVD Technologies Market Size, By End User, 2013¨C2020 (USD Million)
Table 20 U.S. IVD Market Size, By Application, 2013¨C2020 (USD Million)
Table 21 Infectious Disease Incidence in The U.S., 2008¨C2012
Table 22 Human Immunodeficiency Virus (HIV) Prevalence in The U.S., By Region
Table 23 U.S. IVD Market Size, for Infectious Diseases By End User, 2013¨C2020 (USD Million)
Table 24 Diabetes Incidence in The U.S., By Region, 2008¨C2012
Table 25 U.S. IVD Market Size, for Diabetes By End User, 2013¨C2020 (USD Million)
Table 26 Cancer Incidence Rate in The U.S., By Region (Per 100,000 Individuals), 2008¨C2012
Table 27 U.S. IVD Market Size, for Oncology/Cancer By End User, 2013¨C2020 (USD Million)
Table 28 U.S. IVD Market Size, for Cardiovascular Disorders By End User, 2013¨C2020 (USD Million)
Table 29 Obesity Incidence Rate in The U.S., By Region (Per 100,000 Individuals), 2008¨C2012
Table 30 U.S. IVD Market Size, for Endocrine Disorders By End User, 2013¨C2020 (USD Million)
Table 31 Arthritis Incidence in The U.S., By Region, 2011 & 2013
Table 32 U.S. IVD Market Size, for Autoimmune Diseases By End User, 2013¨C2020 (USD Million)
Table 33 U.S. IVD Market Size, for Bone & Mineral-Related Diseases By End User, 2013¨C2020 (USD Million)
Table 34 Asthma Prevalence in The U.S., By Age, 2007-2011
Table 35 U.S. IVD Market Size, for Pulmonary Diseases By End User, 2013¨C2020 (USD Million)
Table 36 U.S. IVD Market Size, for Other Applications By End User, 2013¨C2020 (USD Million)
Table 37 U.S.: IVD Market Size, By End User, 2013¨C2020 (USD Million)
Table 38 U.S.: IVD Market Size for Hospital Laboratories, By Region, 2013¨C2020 (USD Million)
Table 39 U.S.: IVD Market Size for Hospital Laboratories, By Application, 2013¨C2020 (USD Million)
Table 40 U.S.: IVD Market Size for Clinical Laboratories, By Region, 2013¨C2020 (USD Million)
Table 41 U.S.: IVD Market Size for Clinical Laboratories, By Application, 2013¨C2020 (USD Million)
Table 42 U.S.: IVD Market Size for Clinical Laboratories, By Laboratory Size, 2013¨C2020 (USD Million)
Table 43 U.S.: IVD Market Size for Other End User, By Region, 2013¨C2020 (USD Million)
Table 44 U.S.: IVD Market Size for Other End Users, By Application, 2013¨C2020 (USD Million)
Table 45 Growth Strategy Matrix, 2012¨C2015
Table 46 New Product Launches, 2014¨C2015
Table 47 Collaborations, Agreements, & Partnerships, 2014¨C2016
Table 48 Approvals, 2015
Table 49 Mergers & Acquisitions, 2014¨C2016
Table 50 Others, 2014¨C2015

List of Figures (41 Figures)

Figure 1 U.S. in Vitro Diagnostics Market
Figure 2 Research Design
Figure 3 Bottom-Up Approach
Figure 4 Top-Down Approach
Figure 5 Data Triangulation Methodology
Figure 6 U.S. IVD Market Size, By Products & Services, 2015 vs 2020 (USD Million)
Figure 7 U.S. IVD Instruments Market Size, By Type, 2015 vs 2020 (USD Million)
Figure 8 U.S. IVD Market Size, By Technology, 2015 vs 2020 (USD Million)
Figure 9 U.S. IVD Market Size, By Application, 2015 vs 2020 (USD Million)
Figure 10 U.S. IVD Market Size, By End User, 2015 vs 2020 (USD Million)
Figure 11 U.S. IVD Market Size, By Region, 2015 vs 2020 (USD Million)
Figure 12 Growing Prevalence of Chronic Diseases and Increasing Demand for Automated Instruments to Drive Market Growth
Figure 13 Hospital Laboratories Accounted for The Largest Share of The U.S. IVD End-Users Market in 2014
Figure 14 South Region to Dominate The U.S. IVD Market During 2015 to 2020
Figure 15 U.S. in Vitro Diagnostics Market Segmentation, By Product
Figure 16 U.S. in Vitro Diagnostics Market Segmentation, By Technology
Figure 17 U.S. in Vitro Diagnostics Market Segmentation, By Application
Figure 18 U.S. in Vitro Diagnostics Market Segmentation, By End User
Figure 19 U.S. IVD Market: Drivers, Restraints, Opportunities, & Challenges
Figure 20 Number of Patients With Chronic Condition in The U.S. (In Million)
Figure 21 Reagents, The Fastest Growing Segment of The U.S. IVD Market During 2015-2020
Figure 22 The Molecular Diagnostics Segment to Register The Highest Growth During The Forecast Period
Figure 23 Oncology Segment to Register The Highest Growth During The Forecast Period
Figure 24 Prevalence of Cardiovascular Diseases in Adults AGED ¡Ý20 Years
Figure 25 U.S. IVD Market Size, By End User, 2015 vs 2020 (USD Million)
Figure 26 U.S. Clinical Laboratories Market Size, By Type, 2015 vs 2020 (USD Million)
Figure 27 Market Players Actively Adopted New Product Launches as A Key Growth Strategy Between 2012 and 2015
Figure 28 U.S. in Vitro Diagnostics Market Share Analysis, 2014
Figure 29 Battle for Market Share: New Product Launches Was The Key Strategy
Figure 30 Geographic Revenue Mix of The Top 5 Market Players
Figure 31 Company Snapshot: Abbott Laboratories, Inc.
Figure 32 Company Snapshot: Danaher Corporation
Figure 33 Company Snapshot: Johnson and Johnson
Figure 34 Company Snapshot: F. Hoffmann-La Roche Ltd.
Figure 35 Company Snapshot: Siemens Ag
Figure 36 Company Snapshot: Becton, Dickinson and Company
Figure 37 Company Snapshot: Biom¨¦rieux
Figure 38 Company Snapshot: Bio-Rad Laboratories, Inc.
Figure 39 Company Snapshot: Sysmex Corporation
Figure 40 Company Snapshot: Thermo Fisher Scientific, Inc.
Figure 41 Company Snapshot: Qiagen N.V.

【レポートのキーワード】

体外診断(IVD)、アメリカ、免疫測定法、臨床化学、分子診断、微生物

★調査レポート[アメリカの体外診断(IVD)市場:免疫測定法、臨床化学、分子診断、微生物] ( U.S. In Vitro Diagnostics (IVD) Market by Technology (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Microbiology), Application (Infectious Diseases, Diabetes, Cancer, Cardiology), End User (Hospitals & Laboratories) & by Region - Forecast to 2020 / MAM-MD-4174) 販売に関する免責事項
[アメリカの体外診断(IVD)市場:免疫測定法、臨床化学、分子診断、微生物] ( U.S. In Vitro Diagnostics (IVD) Market by Technology (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Microbiology), Application (Infectious Diseases, Diabetes, Cancer, Cardiology), End User (Hospitals & Laboratories) & by Region - Forecast to 2020 / MAM-MD-4174) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆